论文部分内容阅读
目的研究婴幼儿腹泻患者采用双歧杆菌四联活菌片联合蒙脱石散剂进行治疗的临床效果并探讨其临床价值。方法选取2014年1月至2015年1月在项城市第一人民医院进行治疗的50例腹泻患儿,随机分为实验组与对照组,每组25例,实验组采用蒙脱石散剂与双歧杆菌四联活菌片相联合的模式进行治疗,对照组采用单用双歧杆菌四联活菌片的模式进行治疗,比较两组患者的治疗效果。结果实验组痊愈21例,有效4例,总有效率为100%。对照组痊愈16例,有效4例,无效5例,总有效率为80.0%。实验组总有效率明显高于对照组,差异有统计学意义(P<0.05)。实验组呕吐症状消失所需时间、止泻所需时间以及脱水消失所需时间均少于对照组,差异有统计学意义(P<0.05)。两组治疗后血清肿瘤坏死因子-α以及白细胞介素-6水平都降低,实验组降低幅度明显大于对照组降低幅度,两组治疗前以及治疗后差异均有统计学意义(P<0.05)。所有患儿均未出现严重不良反应。结论婴幼儿儿腹泻患者采用双歧杆菌四联活菌联合蒙脱石散剂进行治疗的临床效果显著,并且不良反应少,在临床值得推广。
Objective To study the clinical effect of Bifidobacterium quadricepsis combined with montmorillonite powder in the treatment of infantile diarrhea and to explore its clinical value. Methods Fifty children with diarrhea who were treated in Xiangcheng First People’s Hospital from January 2014 to January 2015 were randomly divided into experimental group and control group with 25 cases in each group. The experimental group was treated with montmorillonite powder and bis The combination of probiotics and live quadriceps were treated in the control group. The control group was treated with Bifidobacterium tetra live viable bacteria alone, and the treatment effect was compared between the two groups. Results The experimental group cured 21 cases, effective in 4 cases, the total effective rate was 100%. The control group cured 16 cases, 4 cases effective, 5 cases ineffective, the total effective rate was 80.0%. The total effective rate of the experimental group was significantly higher than that of the control group, the difference was statistically significant (P <0.05). The time required for vomiting disappearance, the time needed for antidiarrheal, and the time required for dehydration and disappearance in the experimental group were all less than those in the control group, with significant differences (P <0.05). The levels of serum tumor necrosis factor-α and interleukin-6 in both groups decreased after treatment, and the decrease in the experimental group was significantly greater than that in the control group. There was significant difference between the two groups before and after treatment (P <0.05). No severe adverse reactions occurred in all children. Conclusion Infants and young children with diarrhea with bifidobacterium viable together with montmorillonite powder for the treatment of clinical significant effect, and less adverse reactions, the clinical worthy of promotion.